Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
Lexicon Pharmaceuticals (LXRX) announced a virtual webcast titled 'LX9211 - Changing the Paradigm for Treatment of Neuropathic Pain' scheduled for January 28, 2025, from 9:00 a.m. to 11:00 a.m. ET. The event precedes the anticipated topline data release from the Phase 2b PROGRESS trial later this quarter.
The webcast will feature presentations from Lexicon's leadership team, including CEO Mike Exton, VP of Clinical Development Suma Gopinathan, and Chief Medical Officer Craig Granowitz. The event will also include an expert panel discussion on diabetic peripheral neuropathic pain (DPNP) with renowned specialists Dr. Rodica Pop-Busui and Dr. Steve Edelman.
LX9211 is Lexicon's novel, investigational, non-opioid treatment for DPNP. The event will be available in the 'Events' section of Lexicon's website, with a recording accessible after the live broadcast.
Lexicon Pharmaceuticals (LXRX) ha annunciato un webcast virtuale intitolato 'LX9211 - Cambiare il Paradigma per il Trattamento del Dolore Neuropatico' programmato per il 28 gennaio 2025, dalle 9:00 alle 11:00 ET. L'evento precede la tanto attesa pubblicazione dei dati preliminari dall'studio Phase 2b PROGRESS che avverrà entro questo trimestre.
Il webcast presenterà interventi del team dirigente di Lexicon, incluso il CEO Mike Exton, il VP dello Sviluppo Clinico Suma Gopinathan e il Chief Medical Officer Craig Granowitz. L'evento includerà anche una discussione di un panel di esperti sul dolore neuropatico periferico diabetico (DPNP) con i rinomati specialisti Dr. Rodica Pop-Busui e Dr. Steve Edelman.
LX9211 è un trattamento investigativo innovativo e non oppioide di Lexicon per il DPNP. L'evento sarà disponibile nella sezione 'Eventi' del sito web di Lexicon, con una registrazione accessibile dopo la trasmissione in diretta.
Lexicon Pharmaceuticals (LXRX) anunció un webcast virtual titulado 'LX9211 - Cambiando el Paradigma para el Tratamiento del Dolor Neuropático' programado para el 28 de enero de 2025, de 9:00 a.m. a 11:00 a.m. ET. El evento precede la esperada publicación de los datos preliminares del ensayo Phase 2b PROGRESS más tarde este trimestre.
El webcast contará con presentaciones del equipo directivo de Lexicon, incluyendo al CEO Mike Exton, la VP de Desarrollo Clínico Suma Gopinathan y el Director Médico Craig Granowitz. El evento también incluirá una discusión en un panel de expertos sobre dolor neuropático periférico diabético (DPNP) con renombrados especialistas como la Dra. Rodica Pop-Busui y el Dr. Steve Edelman.
LX9211 es un tratamiento no opioide, innovador e investigacional de Lexicon para el DPNP. El evento estará disponible en la sección 'Eventos' del sitio web de Lexicon, con una grabación accesible después de la transmisión en vivo.
Lexicon Pharmaceuticals (LXRX)는 'LX9211 - 신경병성 통증 치료 패러다임 변화'라는 제목의 가상 웹캐스트를 2025년 1월 28일 오전 9시부터 11시까지 ET에 개최한다고 발표했습니다. 이 행사는 이번 분기 중에 예정된 2b 단계 PROGRESS 시험의 주요 데이터 발표에 앞선 것입니다.
웹캐스트에서는 Lexicon의 리더십 팀, CEO Mike Exton, 임상 개발 부사장 Suma Gopinathan, 그리고 최고 의료 책임자 Craig Granowitz의 발표가 있을 예정입니다. 또한 당뇨병성 말초 신경병성 통증 (DPNP)에 대한 전문가 패널 토론도 예정되어 있으며, 저명한 전문가인 Dr. Rodica Pop-Busui와 Dr. Steve Edelman이 참여합니다.
LX9211은 DPNP를 위한 Lexicon의 혁신적인 비-opioid 치료제입니다. 이 행사는 Lexicon 웹사이트의 '이벤트' 섹션에서 확인할 수 있으며, 생중계 후 녹화본도 이용 가능합니다.
Lexicon Pharmaceuticals (LXRX) a annoncé un webinaire virtuel intitulé 'LX9211 - Changer le Paradigme du Traitement de la Douleur Neuropathique', prévu pour le 28 janvier 2025, de 9h00 à 11h00 ET. Cet événement précède la publication attendue des données préliminaires de l'
Le webinaire comportera des présentations de l'équipe dirigeante de Lexicon, y compris le PDG Mike Exton, la VP du Développement Clinique Suma Gopinathan et le Médecin Chef Craig Granowitz. L'événement inclura également une discussion de panel d'experts sur la douleur neuropathique périphérique diabétique (DPNP) avec les spécialistes renommés Dr. Rodica Pop-Busui et Dr. Steve Edelman.
LX9211 est un traitement novateur, d'investigation et non-opioïde de Lexicon pour la DPNP. L'événement sera disponible dans la section 'Événements' du site web de Lexicon, avec un enregistrement accessible après la diffusion en direct.
Lexicon Pharmaceuticals (LXRX) hat ein virtuelles Webcast mit dem Titel 'LX9211 - Den Ansatz zur Behandlung von neuropathischen Schmerzen verändern' angekündigt, das für den 28. Januar 2025, von 9:00 bis 11:00 Uhr ET, geplant ist. Die Veranstaltung precediert die erwartete Veröffentlichung der vorläufigen Daten der Phase 2b PROGRESS-Studie, die später in diesem Quartal stattfinden wird.
Das Webcast wird Präsentationen des Führungsteams von Lexicon beinhalten, einschließlich des CEO Mike Exton, der VP für Klinische Entwicklung Suma Gopinathan und des Chief Medical Officer Craig Granowitz. Darüber hinaus wird die Veranstaltung eine Expertenpanel-Diskussion über diabetische periphere neuropathische Schmerzen (DPNP) mit den renommierten Spezialisten Dr. Rodica Pop-Busui und Dr. Steve Edelman umfassen.
LX9211 ist Lexicons neuartige, investigatium nicht-opioid Behandlung für DPNP. Die Veranstaltung wird im Abschnitt 'Veranstaltungen' auf der Lexicon-Website verfügbar sein, mit einer Aufzeichnung, die nach der Live-Übertragung zugänglich ist.
- Phase 2b PROGRESS trial topline data expected this quarter
- Development of novel non-opioid treatment for significant medical condition (DPNP)
- None.
Event will feature insights on LX9211, Lexicon’s novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNP
THE WOODLANDS, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company will host a virtual webcast: “LX9211 - Changing the Paradigm for Treatment of Neuropathic Pain.” The event will be held from 9:00 a.m. to 11:00 a.m. ET on January 28, 2025.
In advance of topline data from the Phase 2b PROGRESS trial anticipated later this quarter, the event will offer an in-depth overview on LX9211 for the treatment of diabetic peripheral neuropathic pain (DPNP), featuring remarks from Lexicon leaders including:
- Mike Exton, PhD, Chief Executive Officer and Director
- Suma Gopinathan, PhD, Vice President, Clinical Development
- Craig Granowitz, MD, PhD, Senior Vice President and Chief Medical Officer
In addition to presentations by the Lexicon leadership team, the event will include an expert panel and Q&A session on DPNP featuring:
- Rodica Pop-Busui MD, PhD, Jordan Schnitzer Chair in Diabetes | Professor of Medicine and Division Head, Endocrinology, Diabetes and Clinical Nutrition Director, Harold Schnitzer Diabetes Center, Oregon Health & Science University | 2023 President for Medicine and Science, American Diabetes Association
- Steve Edelman, MD, Professor of Medicine, the Division of Endocrinology, Diabetes & Metabolism at University of California San Diego | Veterans Affairs Medical Center | Founder and Director Taking Control Of Your Diabetes (TCOYD)
Register for the event here. The webcast will be available in the “Events” section of the Lexicon website at https://investors.lexpharma.com/news-events/events and a recording of the webcast will be available following the original on-demand date.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in cardiology, neuropathic pain, metabolism and other indications. For additional information, please visit www.lexpharma.com.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
FAQ
When will Lexicon (LXRX) release Phase 2b PROGRESS trial results for LX9211?
What is LX9211 being developed for by Lexicon (LXRX)?
When is Lexicon's (LXRX) virtual webcast on LX9211?
Who are the key speakers at Lexicon's (LXRX) LX9211 webcast?
